ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
From the article
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that meets health needs without the logistical challenges of current treatments, said Rodolfo J. Galindo, MD. The post ACHIEVE results show A1C reduction, weight loss in type 2 diabetes appeared first on ADA Meeting News .
Continue reading on adameetingnews.orgYou might also wanna read
CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs
Orforglipron is an FDA-approved non-peptide oral GLP-1 pill being studied as an alternative to injectable weight-loss drugs like Ozempic and
news.cuanschutz.edu·2d agoNew weight loss pill beats oral Ozempic in major trial
ScienceDaily·1d ago
FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements
The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP
medicaldaily.com·1d ago
Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial
theguardian.com·1mo ago
National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
doi.org·1mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
today.ucsd.edu·7mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.